Journal of VitreoRetinal Diseases最新文献_第9页

Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis. 脉络膜上腔给药治疗非感染性葡萄膜炎引起的黄斑水肿

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-04-25 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241246314

Ye Huang, Charlene Choo, Shelley Hancock, Thomas A Ciulla, Charles C Wykoff, Jessica G Shantha, Steven Yeh

{"title":"Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis.","authors":"Ye Huang, Charlene Choo, Shelley Hancock, Thomas A Ciulla, Charles C Wykoff, Jessica G Shantha, Steven Yeh","doi":"10.1177/24741264241246314","DOIUrl":"10.1177/24741264241246314","url":null,"abstract":"Purpose: To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. Methods: A synthesis of the literature was performed. Results: In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. Conclusions: The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 4","pages":"401-409"},"PeriodicalIF":0.5,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

What Factors Lead to Disparities in Healthcare and Healthcare Providers and What Should Be Done to Address Them? 哪些因素导致了医疗保健和医疗保健提供者之间的差异？

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-04-17 eCollection Date: 2024-05-01 DOI: 10.1177/24741264241246585

John T Thompson

引用次数: 0

From the Editor-in-Chief. 主编的话

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-03-08 eCollection Date: 2024-03-01 DOI: 10.1177/24741264241234111

Timothy G Murray

引用次数: 0

Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma. 治疗脉络膜黑色素瘤的钇-90巩膜斑近距离放射治疗。

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-02-18 eCollection Date: 2024-03-01 DOI: 10.1177/24741264241227684

Paul T Finger

{"title":"Yttrium-90 Episcleral Plaque Brachytherapy for Choroidal Melanoma.","authors":"Paul T Finger","doi":"10.1177/24741264241227684","DOIUrl":"10.1177/24741264241227684","url":null,"abstract":"Purpose: To describe the first use of high-dose-rate yttrium-90 disc brachytherapy for choroidal melanoma. Methods: A 72-year-old patient had a cT1-category choroidal melanoma characterized by the presence of orange pigment, increasing subretinal fluid (SRF), and enlarging tumor thickness. It was treated with single-session, light-guided, light-defined yttrium-90-disc brachytherapy. Results: A specialized handheld applicator provided with 4 encircling lights was used to guide plaque placement and localize treatment. Unlike low-dose-rate plaques, high-dose-rate yttrium-90 required only 3 minutes 39 seconds. In this case, treatment did not require episcleral sutures, muscle relocation, outpatient dwell time, or a second surgery. High-dose-rate treatment improved radiation safety by eliminating perioperative exposure to health care personnel, the community, and the family. At the 13-month follow-up, the SRF and tumor thickness were diminished. There was no secondary cataract, radiation retinopathy, maculopathy, or optic neuropathy, and the visual acuity was 20/20. Conclusions: Yttrium-90 brachytherapy allowed for single-surgery, minimally invasive, outpatient irradiation of a choroidal melanoma.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 2","pages":"210-214"},"PeriodicalIF":0.6,"publicationDate":"2024-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Occlusive Retinal Vasculitis After a Single Injection of Pegcetacoplan. 单次注射 Pegcetacoplan 后的闭塞性视网膜血管炎

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-01-30 eCollection Date: 2024-03-01 DOI: 10.1177/24741264241228648

Mariana Abi Karam, Janet L Davis, Stephen G Schwartz

引用次数: 0

Ophthalmologic Presentations of Incontinentia Pigmenti. 皮格蒙特失禁症的眼科表现。

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-01-28 eCollection Date: 2024-03-01 DOI: 10.1177/24741264241227680

Ravneet S Rai, Albert S Li, Philip J Ferrone

{"title":"Ophthalmologic Presentations of Incontinentia Pigmenti.","authors":"Ravneet S Rai, Albert S Li, Philip J Ferrone","doi":"10.1177/24741264241227680","DOIUrl":"10.1177/24741264241227680","url":null,"abstract":"Purpose: To characterize treatments and outcomes in incontinentia pigmenti. Methods: Cases of incontinentia pigmenti were consecutively identified from a retina practice. Inclusion criteria were patients with incontinentia pigmenti with at least 6 months of follow-up. All patients had a full ophthalmic examination, including imaging with widefield fundus photography and widefield fluorescein angiography. Eyes with areas of avascular retina were treated with laser photocoagulation (except for 1 eye with mild changes). Results: Thirty-six eyes of 18 patients with incontinentia pigmenti were included. The median age at presentation was 11 months. On presentation, 7 eyes had a visual acuity (VA) of 20/40 or better and 3 eyes had VA of 20/50 to 20/100. The remaining 26 eyes could fix and follow or had at least light perception (LP) VA given the patients' young age. Of the 36 eyes, 20 (56%) had retinal involvement. The mean follow-up for treated patients was 6.9 years. Seventy-four percent of treated eyes required 1 laser session only. No eye that received laser treatment subsequently developed a retinal detachment. Of the 26 eyes with initial fix-and-follow or LP VA, 12 had Snellen or Allen VA testing at follow-up. Nine of these eyes had a follow-up VA of 20/40 or better. Of 10 eyes with a Snellen or Allen VA recorded at the initial visit, 9 had a final VA that was the same or improved. Conclusions: Laser photocoagulation was effective in treating patients with retinal manifestations of incontinentia pigmenti. Except for 1 eye, VA remained stable at the final follow-up.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 2","pages":"186-191"},"PeriodicalIF":0.6,"publicationDate":"2024-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10924593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From the Editor-in-Chief. 主编的话

IF 0.5

Journal of VitreoRetinal Diseases Pub Date : 2024-01-10 eCollection Date: 2024-01-01 DOI: 10.1177/24741264231222514

Timothy G Murray

引用次数: 0

Effect of Race and Insurance Status on Treatment and Outcomes in Diabetic Retinopathy: Analysis of 43 274 Eyes Using the IRIS Registry 种族和保险状况对糖尿病视网膜病变治疗和结果的影响：利用 IRIS 登记对 43 274 只眼睛进行分析

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-01-04 DOI: 10.1177/24741264231221607

Jay Maturi, V. Maturi, Adrienne W. Scott, Kathryn A. Carson, Thomas Ciulla, Raj Maturi

{"title":"Effect of Race and Insurance Status on Treatment and Outcomes in Diabetic Retinopathy: Analysis of 43 274 Eyes Using the IRIS Registry","authors":"Jay Maturi, V. Maturi, Adrienne W. Scott, Kathryn A. Carson, Thomas Ciulla, Raj Maturi","doi":"10.1177/24741264231221607","DOIUrl":"https://doi.org/10.1177/24741264231221607","url":null,"abstract":"Purpose: To examine disparities in visual acuity (VA) outcomes 1 year and 2 years after initiation of diabetic retinopathy (DR) or diabetic macular edema (DME) treatment in patients based on race/ethnicity and insurance status, accounting for disease severity. Methods: This retrospective analysis used the IRIS Registry and included DR patients older than 18 years with documented antivascular endothelial growth factor (anti-VEGF) treatment and VA data for at least 2 years. International Classification of Diseases, Tenth Revision, Clinical Modification codes were used to determine the severity of DR and DME presence. VA outcomes were assessed using multivariable linear regressions and anti-VEGF drug use by multivariable logistic regressions, with race and insurance status as independent variables. Main outcome measures comprised the mean VA change at 1 year and 2 years and percentage of patients treated with bevacizumab. Results: Among 43 274 eyes, White patients presented with a higher mean VA and lower mean DR severity than Black and Hispanic patients. Multivariable logistic regression showed Hispanic patients were significantly more likely to be treated with bevacizumab than White patients across all insurance types, controlling for disease severity and VA. After 1 year, the letter improvement was 1.73, 1.33, and 1.13 in White, Black, and Hispanic patients, respectively. Multivariable linear regression suggested that across races, Medicaid-insured patients had significantly smaller gains in VA than privately insured patients. Conclusion: Race-based and insurance-based differences in 1-year and 2-year outcomes after anti-VEGF treatment for DR and anti-VEGF treatment patterns suggest a need to ensure earlier and more effective treatment of minority and underserved patients nationally.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"31 8","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139384395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Characteristics and Risk Factors for Rhegmatogenous Retinal Detachment Related to Endophthalmitis 与眼底病相关的流泪性视网膜脱离的特征和风险因素

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-01-02 DOI: 10.1177/24741264231218509

Cary R. Baxter, Martin G. Mccandless, Albert L. Lin

{"title":"Characteristics and Risk Factors for Rhegmatogenous Retinal Detachment Related to Endophthalmitis","authors":"Cary R. Baxter, Martin G. Mccandless, Albert L. Lin","doi":"10.1177/24741264231218509","DOIUrl":"https://doi.org/10.1177/24741264231218509","url":null,"abstract":"Purpose: To evaluate the risk factors for the development of concurrent or delayed-onset rhegmatogenous retinal detachment (RRD) related to endophthalmitis as well as the anatomic and visual outcomes with subsequent RRD repair. Methods: In this retrospective case study, a 2-tailed t test (continuous) and Fisher exact test were used to determine statistical significance of the observed findings. The relative risk (RR) and 95% confidence intervals (CIs) were calculated to assess statistical significance. Results: Of the 170 patients included, 22 were found to have a concurrent or subsequent RRD. Initial treatment with pars plana vitrectomy (PPV) (RR, 3.544; 95% CI, 1.650-7.614), aphakia (RR, 4.150; 95% CI, 1.434-12.011), endogenous endophthalmitis (RR, 2.684; 95% CI, 1.065-6.764), and posterior synechiae (RR, 3.026; 95% CI, 1.408-6.505) were statistically significant risk factors for RRD. Anatomically successful repair was achieved in 77.7% of patients. Conclusions: In addition to preexisting risk factors, the initial treatment of endophthalmitis may be a significant risk factor for RRD development, with a higher incidence of subsequent RRD in patients who have PPV as the initial treatment of endophthalmitis.","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"19 4","pages":""},"PeriodicalIF":0.6,"publicationDate":"2024-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139452619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Subfoveal Choroidal Neovascular Membrane Secondary to Idiopathic Intracranial Hypertension 特发性颅内高压继发的眼底脉络膜新生血管膜

IF 0.6

Journal of VitreoRetinal Diseases Pub Date : 2024-01-02 DOI: 10.1177/24741264231218539

Austin Pereira, Prem A H Nichani, Peng Yan, J. Micieli

引用次数: 0